Europe’s microbiome therapeutics market may soon see a major new entrant. IdB Holding and Nestlé Health Science have announced a licensing agreement for the development and future commercialization in Europe of VOWST®, the first oral live biotherapeutic product approved in the United States for the prevention of recurrent Clostridioides difficile infection, or rCDI.

The deal marks a strategic step for both the Italian group IdB Holding and Nestlé Health Science, which aims to expand one of the most advanced clinical applications of microbiome medicine into the European market. Commercial launch, however, remains subject to approval by the European Medicines Agency, a regulatory pathway the two companies will pursue jointly over the coming years.

A market looking for new therapeutic options

Recurrent Clostridioides difficile infection remains one of the most challenging gastrointestinal infections associated with dysbiosis. Although antibiotics are effective in treating the acute episode, a substantial proportion of patients experience further recurrences, entering a difficult-to-break clinical cycle.

The condition is associated with increased morbidity and mortality and places a significant economic burden on healthcare systems. In the United States, the average annual cost associated with a patient with rCDI has been estimated at around $43,000, underscoring the potential value for health authorities of preventive strategies capable of reducing hospitalizations and repeated courses of treatment.

VOWST® fits into this scenario as an oral therapy based on bacterial spores derived from fecal microbiota. Its goal is to restore microbial balance in the gut after antibiotic treatment, thereby reducing the risk of further infection.

From FDA approval to Europe: the next regulatory challenge

In 2023, VOWST® received approval from the U.S. Food and Drug Administration as the first oral live biotherapeutic product indicated to prevent the recurrence of C. difficile infection in adults following antibiotic therapy.

Under the newly announced agreement, IdB Holding and Nestlé Health Science will collaborate on the clinical and regulatory activities required to support a European marketing authorization application. Once EMA approval is obtained, IdB will be able to exercise the acquired rights to commercialize the product across European markets.

For the microbiome sector, this is a particularly important development. Over the past few years, many companies have invested in the development of live microbiological medicines, but the regulatory path has proven complex, and only a limited number of products have reached the market. The experience gained by VOWST in the United States may therefore become an important precedent for the broader industry.

A new industrial chapter for IdB Holding

The agreement also represents a strategic turning point for IdB Holding, the Italian group founded in 1921 by the Della Beffa family and known internationally above all through Indena, one of the world’s leading producers of plant-derived active ingredients for the pharmaceutical and nutraceutical industries.

According to the company, the project will lead to the creation of a dedicated new company focused on the commercialization of VOWST® and on the development of further opportunities in innovative therapies.

“The signing of this partnership is the first major step in this project, a milestone that reflects trust, collaboration and the exchange of expertise between IdB Holding and Nestlé Health Science,” said Gianluigi Frozzi, President of IdB Holding. “This initiative opens an exciting new chapter for IdB, which will establish a dedicated company with the aim of commercializing VOWST® and bringing new therapies to European patients affected by severe diseases that still lack effective treatment options.”

The initiative also confirms the growing interest of Italian companies in microbiome-based therapies, a field that until only a few years ago was largely dominated by U.S. biotech start-ups.

Nestlé strengthens its microbiome strategy

For Nestlé Health Science, the agreement is part of a long-term strategy that identifies the microbiome as one of the most promising platforms for therapeutic and nutritional innovation.

In recent years, the Swiss group’s healthcare business unit has made significant investments in microbiome research through acquisitions, partnerships and dedicated research programs. The collaboration with IdB now aims to translate that expertise into the geographic expansion of VOWST®, making the therapy available to European patients as well.

“This agreement reflects the value of VOWST® and our confidence in its clinical profile and long-term potential,” said Luis Briz, President of Professional Health at Nestlé Health Science. “Our collaboration with IdB Holding represents a significant step toward making this innovative therapy available to European patients.”

A signal for the microbiome industry as a whole

Beyond the commercial prospects of a single product, the deal is a sign of the growing maturity of the microbiome ecosystem. After years dominated mainly by academic research and preclinical development, the field is now entering a phase in which industrial partnerships, regulatory pathways and market access strategies are becoming central.

Should the European program reach a successful conclusion, VOWST® could become one of the first microbiome-based therapies to be authorized and commercialized at scale across the continent. In doing so, it may help shape the future competitive landscape of a market that analysts and investors continue to view as one of the most promising areas of precision medicine.